← All trials
NCT04691908
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- Jul 30, 2021
- First posted
- Dec 31, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 3000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Research Institute for Biological Safety ProblemsLead sponsor
- Government of KazakhstanCollaborator
- City polyclinic No. 4 of the UZO of AlmatyCollaborator
- Clinic of the International Institute of Postgraduate EducationCollaborator
- Government of KazakhstanStudy director
- Government of KazakhstanStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.